Introduction: Tranexamic acid (TXA) is an antifibrinolytic agent widely used in surgery to decrease bleeding and reduce the need for blood product transfusion. The role of TXA in urology is not well-summarized. We conducted a systematic review of studies reporting outcomes of TXA use in urological surgery.
Methods: A comprehensive search was conducted from the following databases: PubMed, Embase, Cochrane Library, and Web of Science. Two reviewers performed title and abstract screening, full-text review, and data collection. Primary outcomes included estimated blood loss (EBL), decrease in hemoglobin, decrease in hematocrit, and blood transfusion rates. Secondary outcomes included TXA administration characteristics, length of stay, operative time, and postoperative thromboembolic events.
Results: A total of 26 studies consisting of 3261 patients were included in the final analysis. These included 11 studies on percutaneous nephrolithotomy, 10 on transurethral resection of prostate, three on prostatectomy, and one on cystectomy. EBL, transfusion rate, hemoglobin drop, operative time, and length of stay were significantly improved with TXA administration. In addition, the use of TXA was not associated with an increased risk of venous thromboembolism (VTE ). The route, dosage, and timing of TXA administration varied considerably between included studies.
Conclusions: TXA use may improve blood loss, transfusion rates, and perioperative parameters in urological procedures. In addition, there is no increased risk of VTE associated with TXA use in urological surgery; however, there is still a need to determine the most effective TXA administration route and dose. This review provides evidence-based data for decision-making in urological surgery.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10263287 | PMC |
| http://dx.doi.org/10.5489/cuaj.8254 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The optimal dose of intravenous tranexamic acid for reducing blood loss in spinal surgery: a network meta-analysis.
BMC Musculoskelet Disord
December 2024
Shanxi Bethune Hospital, Third Hospital of Shanxi Medical University, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, China.
Background: This study aims to evaluate the optimal dose of intravenous tranexamic acid (TXA) for reducing blood loss in spinal surgery.
Methods: A systematic search was conducted in the PubMed, Embase, Cochrane Library database from inception until November 2023. Randomized controlled trials (RCTs) incorporating diverse TXA dosing regimens for spinal surgery were included.
Tranexamic acid in hip and spine surgery for children with cerebral palsy - a PRISMA-compliant scoping review.
Syst Rev
December 2024
Department of Paediatrics, The Royal Children's Hospital, University of Melbourne, 50 Flemington Road, Parkville, VIC, 3052, Australia.
Many children with cerebral palsy (CP) are frail and require major hip and/or spine surgeries associated with substantial blood loss. Tranexamic acid (TXA) is commonly used to reduce blood loss, but there is uncertainty around the optimal dose and timing of administration. There have been reviews in sub-populations and specific dosing regimens, but a broad overview of the available literature is lacking.
View Article and Find Full Text PDFThe efficacy and safety of topical combined with intravenous administration of tranexamic acid in spine surgery: a systematic review and meta-analysis.
BMC Musculoskelet Disord
December 2024
Department of Orthopedics, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Taizhou, Zhejiang, 317000, China.
Background: There is controversy regarding the efficacy of intravenous combined topical tranexamic acid. We conducted this study to systematically assess the effectiveness of intravenous combined topical tranexamic acid (combined TXA) in spinal surgery to guide clinical practice.
Methods: The review process was conducted according to the PRISMA guidelines.
Post acne erythema (PAE) is a common sequela of acne inflammation, and it refers to telangiectasia and erythematous lesions remaining after the acne treatment. Although some PAE may improve over time, persisting PAE might be esthetically undesirable for patients. The efficacy of various treatment options for PAE has been investigated in many studies but there exists no gold standard treatment modality.
View Article and Find Full Text PDFAssociation between IV and topical tranexamic acid use and periprosthetic joint infections in hip and knee arthroplasty: a retrospective study.
BMC Musculoskelet Disord
December 2024
Department of Orthopaedic Surgery, Kaohsiung Chang Gung Memorial Hospital, No. 123, Dapi Road, Niaosong District, Kaohsiung, 833, Taiwan.
Article Synopsis
- Anemia and blood transfusions increase the risk of periprosthetic joint infections (PJI), and tranexamic acid (TXA) is known to reduce surgery-related blood loss and transfusions.
- A retrospective study involving over 8,000 patients examined the effects of TXA on PJI rates following total joint arthroplasty (TJA), comparing those who received TXA (either intravenous or topical) to those who did not.
- Results indicated that TXA significantly reduced PJI occurrences (1.1% vs. 2.1%), decreased blood transfusion rates, and led to shorter hospital stays, with no significant differences in venous thromboembolism or readmission rates.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!